Search

Jialu Guo, 1, 2 Jinyi Tong, 1, 2 Jianfeng Zheng 2, 3 1Department of the Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, 310008, People’s Republic of China; 2Department of Obstetrics and Gynecology, Hangzhou Women’s Hospital (Hangzhou Maternity and Child Health Care Hospital), Hangzhou, Zhejiang Province, 310008, People’s Republic of China; 3Department of Obstetrics and Gynecology, Affiliated Hangzhou Hospital, Nanjing Medical University, Hangzhou, Zhejiang Province, 310008, People’s Republic of ChinaCorrespondence: Jinyi TongDepartment of the Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou Women’s Hospital (Hangzhou Maternity and Child Health Care Hospital), Hangzhou, Zhejiang Province, 310008, People’s Republic of ChinaTel +86 13588818180Email tongjinyi252@zju.edu.cnAbstract: Endometrial cancer (EC) is one of the most common malignant tumors of the female reproductive tract. EC patients have high morbidity and mortality rates and remain an important cause of cancer-related morbidity and mortality worldwide. More and more studies have shown that a large number of non-coding RNAs (such as microRNAs and long non-coding RNAs) are associated with the occurrence of diseases. Circular RNAs (circRNAs) is an endogenous non-coding RNA. It has a unique covalent structure. Many studies in recent years have found circRNAs differential expression in a variety of tumor tissues compared to matched normal tissues. In endometrial carcinoma, there also are multiple circRNAs differentially expressed and therefore circRNAs perhaps can be used as a diagnostic and prognosis biomarkers of EC. In this review, we described the biogenesis, function and characteristics of circRNAs, and the circRNAs with potential influence and clinical significance on the development of EC were summarized. Adenocarcinoma is the most common form of EC, so this review focuses on endometrioid adenocarcinoma.Keywords: circRNA, biogenesis, back-splicing, function, endometrial cancer, biomarker

Additional file 2: Figure S1.The K-M survival curve of Stage II based on the risk model. The p value was indistinctive.

Additional file 4: Figure S1. Immunity microenvironment analysis.

Additional file 4: Figure S1. Immunity microenvironment analysis.